What is the appropriate dose of N‑acetylcysteine (NAC) for an adult with acute kidney injury (AKI)?

N-Acetylcysteine Dosing in Acute Kidney Injury

For contrast-induced AKI prevention, use oral NAC 1,200 mg twice daily for 2 days (starting before contrast exposure) together with IV isotonic crystalloids, though the evidence for efficacy is weak and conflicting. 1

Context and Evidence Quality

The KDIGO guidelines suggest (weak recommendation, 2D) using oral NAC with IV hydration for contrast-induced AKI prevention 1. However, this recommendation is controversial and based on limited evidence:

The Evidence Against NAC

• A large 2,308-patient RCT (ACT trial) showed no benefit: oral NAC 1,200 mg twice daily for 2 days showed identical AKI rates (12.7% vs 12.7%) compared to placebo 2
• Meta-analyses reveal bias: When only high-quality trials are analyzed, NAC shows no effect (RR 1.05,95% CI 0.73-1.53), while low-quality studies showed apparent benefit (RR 0.63) 2
• The Canadian Society of Nephrology concluded NAC benefits were "confined to trials with high risk of bias" and does not support its use 2

Why Guidelines Still Suggest It

Despite lack of proven efficacy, oral NAC remains in guidelines because it is inexpensive, has minimal side effects at standard doses, and poses little harm 1. The KDIGO commentary explicitly states the recommendation is "not inappropriate despite questions of its efficacy" 1.

Specific Dosing Regimens

For Contrast-Induced AKI Prevention (Oral)

• Dose: 1,200 mg orally twice daily
• Duration: 2 days (4 total doses: 2 before and 2 after contrast)
• Must be combined with: IV isotonic crystalloids (1-1.5 mL/kg/hr)
• Never use NAC alone without IV hydration in high-risk patients 1

For Acetaminophen Toxicity (IV - FDA Approved)

This is the only FDA-approved indication for IV NAC in AKI:

• Loading dose: 150 mg/kg IV over 1 hour
• Second dose: 50 mg/kg IV over 4 hours
• Third dose: 100 mg/kg IV over 16 hours
• Total duration: 21 hours (300 mg/kg total) 3

Intravenous NAC for Non-Acetaminophen AKI

IV NAC should NOT be routinely used for contrast-induced or other forms of AKI 1. The guidelines explicitly state:

• IV NAC is "associated with potentially serious adverse effects" including anaphylaxis 1, 4
• "In the absence of sound data supporting its effectiveness, should not be routinely administered" 1

Research Evidence Shows Mixed Results

Recent studies demonstrate inconsistent findings:

• Cardiac surgery: One study using high-dose IV NAC (150 mg/kg bolus + 50 mg/kg × 6 hours) showed reduced AKI (28.6% vs 57.1%, p=0.016) 5, but another study using similar dosing found no benefit (32% vs 35%, p=0.695) 6
• General contrast exposure: A 500-patient study found no benefit from high-dose IV NAC or sodium bicarbonate compared to saline alone 7
• Meta-analysis: Neither oral nor IV NAC decreases contrast-induced nephropathy risk 8

Critical Caveats

1. No agents are recommended for treatment or prevention of established AKI in adults (except theophylline in neonates) 1
2. IV hydration is the cornerstone: NAC should never replace proper volume expansion with isotonic fluids 1
3. Timing matters: For contrast procedures, NAC must be started before exposure when possible 1
4. Risk vs benefit: Given weak evidence, NAC use is reasonable only because oral formulation is safe and cheap, not because of proven efficacy 1, 2
5. Asthma warning: Use IV NAC with extreme caution in asthmatics due to bronchospasm risk; one patient death reported 3

Practical Algorithm

For patients at high risk of contrast-induced AKI:

1. Prioritize IV isotonic saline or sodium bicarbonate (1-1.5 mL/kg/hr starting 6-12 hours before procedure)
2. Consider adding oral NAC 1,200 mg twice daily × 2 days if no contraindications
3. Use lowest contrast dose possible with iso-osmolar or low-osmolar agents
4. Monitor creatinine at 48-72 hours post-procedure

For acetaminophen overdose with AKI:

1. Use FDA-approved IV NAC protocol (150→50→100 mg/kg over 21 hours)
2. Monitor hepatic and renal function throughout
3. Continue beyond 21 hours if acetaminophen levels remain detectable or transaminases rising 3

For other causes of AKI:

• No evidence supports NAC use
• Focus on treating underlying cause and supportive care